Benitec Biopharma Inc. (BNTC)
| Market Cap | 296.15M -31.0% |
| Revenue (ttm) | n/a |
| Net Income | -45.55M |
| EPS | -0.98 |
| Shares Out | 34.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,634 |
| Open | 8.81 |
| Previous Close | 8.74 |
| Day's Range | 8.24 - 8.94 |
| 52-Week Range | 7.89 - 16.31 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 23.29 (+174.32%) |
| Est. Earnings | Nov 13, 2026 |
About BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BNTC stock is "Strong Buy." The 12-month stock price target is $23.29, which is an increase of 174.32% from the latest price.
News
Benitec Biopharma announces interim results from BB-301 trial
Benitec Biopharma (BNTC) announced interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Patients treated with high dose BB-301 and continued durable improvements for P...
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with ...
Benitec Biopharma initiated with an Outperform at Raymond James
Raymond James analyst Tiago Fauth initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $14 price target Benitec is a clinical-stage biotechnology company developing BB-301, a p...
Benitec Biopharma Proxy statement: Proxy filing
Benitec Biopharma filed a proxy statement on October 20, 2026, providing details for shareholder voting and corporate governance matters.
Benitec Biopharma Proxy statement: Proxy filing
Benitec Biopharma filed a proxy statement on October 20, 2026, providing details for shareholder voting and corporate governance matters.
Benitec Biopharma says BB-301 pivotal still on track for mid-2027
Benitec announced formal FDA feedback following a Type C meeting in Q3. Discussions on an open-label, single-arm pivotal study for BB-301 are ongoing. The FDA requested additional available data, incl...
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
The BB-301 pivotal trial remains on track to begin in mid-2027 Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested ...
Benitec Biopharma price target raised to $17 from $16 at Wedbush
Wedbush raised the firm’s price target on Benitec Biopharma (BNTC) to $17 from $16 and keeps an Outperform rating on the shares. The firm says the FY26 update reported good…
Benitec Biopharma price target raised to $17 from $16 at Wedbush
Wedbush analyst Yun Zhong raised the firm’s price target on Benitec Biopharma (BNTC) to $17 from $16 and keeps an Outperform rating on the shares. The firm says the FY26…
Benitec Biopharma files $200M mixed securities shelf
17:11 EDT Benitec Biopharma (BNTC) files $200M mixed securities shelf
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safe...
Benitec Biopharma Earnings release: Q4 2026
Benitec Biopharma released its Q4 2026 earnings on September 14, 2026, summarizing the period's financial results.
Benitec Biopharma Annual report: Q4 2026
Benitec Biopharma has published its Q4 2026 annual report on September 14, 2026.
Benitec Biopharma Registration statement: Registration filing
Benitec Biopharma filed a registration statement on September 14, 2026, providing details about a securities offering with the SEC.
Wedbush bullish on Benitec Biopharma, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target The firm believes that BB-301, an AAV gene therapy that has allowed…
Benitec Biopharma initiated with an Outperform at Wedbush
Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target
Guggenheim downgrades Benitec to Neutral, terminates coverage
Guggenheim downgraded Benitec Biopharma (BNTC) to Neutral from Buy without a price target while subsequently terminating coverage of the name. Benitec is engaging with the FDA mid-year to formalize th...
Benitec Biopharma downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Debjit Chattopadhyay downgraded Benitec Biopharma (BNTC) to Neutral from Buy with no price target
Benitec Biopharma Slides: Corporate presentation
Benitec Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 2...
Benitec Biopharma Earnings release: Q3 2026
Benitec Biopharma released its Q3 2026 earnings on May 14, 2026, summarizing the period's financial results.
Benitec Biopharma Quarterly report: Q3 2026
Benitec Biopharma has published its Q3 2026 quarterly earnings report on May 14, 2026.
Benitec Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $25 price target BB-301 represents “an exciting opportunity in the rare disease space,” particularly for treat...
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the ...
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genet...